DDrare: Database of Drug Development for Rare Diseases

229. 肺胞蛋白症（自己免疫性又は先天性）
［臨床試験数：35，薬物数：30（DrugBank：8），標的遺伝子数：3，標的パスウェイ数：12］

Searched query = "Autoimmune pulmonary alveolar proteinosis", "Congenital pulmonary alveolar proteinosis", "Hereditary pulmonary alveolar proteinosis", "Pulmonary alveolar proteinosis", "PAP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Device: Centricyte 1000; Diagnostic Test: Abdominal and liver ultrasound.; Diagnostic Test: Brain MRI; Diagnostic Test: Methionine/homocysteine Dosage; Diagnostic Test: Thoracic CT scan; GM-CSF; GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim); GM-CSF [Leukine (Sargramostim)]; GM-CSF inhalation therapy; Granulocyte-macrophage colony stimulating factor (GM-CSF); Homocysteine; Leukine; Liberase Enzyme (Roche); MOLGRAMOSTIM; Methionine; Molgramostim; Molgramostim 300 mcg nebuliser solution; Molgramostim Nebuliser solution 300 mcg; Pioglitazone; Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution; Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF); Procedure: WLL; Procedure: Whole Lung Lavage(WLL); RhGM-CSF; RhGm-CSF; Rituximab; Sargramostim; Sterile Normal Saline for Intravenous Use; Vitamin B12; Vitamin B12, B9, B6, C supplementation

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01842386 (ClinicalTrials.gov)	April 29, 2014	25/4/2013	Rituximab for Anti-cytokine Autoantibody-Associated Diseases	Rituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated Diseases	Pulmonary Alveolar Proteinosis (PAP);Severe Mucocutaneous Candidoasis	Drug: Rituximab	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Active, not recruiting	18 Years	N/A	All	7	Phase 1	United States
2	NCT00552461 (ClinicalTrials.gov)	January 2007	31/10/2007	Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis	Prospective Open-Label Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis	Pulmonary Alveolar Proteinosis;Primary Disease	Drug: rituximab	East Carolina University	Genentech, Inc.	Recruiting	18 Years	N/A	Both	10	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01842386
(ClinicalTrials.gov)

April 29, 2014

25/4/2013

Rituximab for Anti-cytokine Autoantibody-Associated Diseases

Rituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated Diseases

Pulmonary Alveolar Proteinosis (PAP);Severe Mucocutaneous Candidoasis

Drug: Rituximab

National Institute of Allergy and Infectious Diseases (NIAID)

NULL

Active, not recruiting

18 Years

N/A

All

Phase 1

United States

NCT00552461
(ClinicalTrials.gov)

January 2007

31/10/2007

Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis

Prospective Open-Label Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis

Pulmonary Alveolar Proteinosis;Primary Disease

Drug: rituximab

East Carolina University

Genentech, Inc.

Recruiting

18 Years

N/A

Both

Phase 2

United States